Evolent Health, Inc (EVH) Receives $27.50 Average Price Target from Brokerages

Evolent Health, Inc (EVH) Receives $27.50 Average Price Target from Brokerages

Shares of Evolent Health, Inc (NYSE:EVH) have received an average recommendation of “Buy” from the ten research firms that are presently covering the company. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $27.50.

A number of equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Evolent Health from a “buy” rating to a “hold” rating in a report on Monday, January 23rd. Jefferies Group LLC set a $28.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a report on Monday, January 16th. Wells Fargo & Company upgraded shares of Evolent Health from a “market perform” rating to an “outperform” rating in a report on Friday, January 13th. Cantor Fitzgerald assumed coverage on shares of Evolent Health in a report on Thursday, January 5th. They issued an “overweight” rating and a $26.00 target price for the company. Finally, TheStreet downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Monday, December 5th.

In other Evolent Health news, President Seth Blackley sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $17.98, for a total value of $539,400.00. Following the sale, the president now owns 854,848 shares in the company, valued at approximately $15,370,167.04. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Michael D’amato acquired 10,000 shares of the stock in a transaction on Monday, November 14th. The stock was bought at an average price of $17.18 per share, for a total transaction of $171,800.00. Following the transaction, the director now owns 18,183 shares in the company, valued at approximately $312,383.94. The disclosure for this purchase can be found here. 8.85% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in Evolent Health by 23.8% in the third quarter. BlackRock Inc. now owns 4,506 shares of the company’s stock valued at $111,000 after buying an additional 867 shares in the last quarter. BlackRock Group LTD raised its stake in Evolent Health by 201.3% in the third quarter. BlackRock Group LTD now owns 7,270 shares of the company’s stock valued at $178,000 after buying an additional 4,857 shares in the last quarter. Barclays PLC bought a new stake in Evolent Health during the second quarter valued at approximately $144,000. BlackRock Advisors LLC raised its stake in Evolent Health by 80.6% in the third quarter. BlackRock Advisors LLC now owns 8,540 shares of the company’s stock valued at $210,000 after buying an additional 3,811 shares in the last quarter. Finally, American International Group Inc. raised its stake in Evolent Health by 14.9% in the second quarter. American International Group Inc. now owns 8,761 shares of the company’s stock valued at $168,000 after buying an additional 1,134 shares in the last quarter. Institutional investors and hedge funds own 51.72% of the company’s stock.

Evolent Health (NYSE:EVH) opened at 18.10 on Friday. The stock has a 50 day moving average of $16.81 and a 200 day moving average of $21.15. The company’s market cap is $1.23 billion. Evolent Health has a 52 week low of $8.14 and a 52 week high of $26.84.

Evolent Health (NYSE:EVH) last announced its earnings results on Wednesday, November 9th. The company reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.02. The business earned $60.20 million during the quarter, compared to the consensus estimate of $58.35 million. Evolent Health had a negative net margin of 69.04% and a negative return on equity of 5.54%. The firm’s revenue was up 39.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.16) earnings per share. Equities research analysts predict that Evolent Health will post ($0.59) EPS for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

Related posts

Leave a Comment